Glioblastoma multiforme is the historical name for glioblastoma, an aggressive and highly malignant primary brain tumor with poor survival outcomes. It is characterized by rapid growth, infiltrative behavior, and frequent recurrence despite multimodal treatment. Clinical management usually includes maximal safe resection followed by chemoradiation.
ImmunityBio's stock jumped 41.9% following the European Commission's conditional marketing authorization for Anktiva combined with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer across 33 European countries.
The FDA has approved Novocure's Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment for this patient group in decades. A trial of 571 patients showed a two-month improvement in overall survival when combined with chemotherapy.
The FDA approved Novocure's Optune Pax device for locally advanced pancreatic cancer treatment alongside chemotherapy, marking the first new treatment option in this indication since 1996. Phase III trial data showed statistically significant survival improvement.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07553520 |
Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients |
WITHDRAWN | NA |
| NCT07416188 |
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma |
RECRUITING | PHASE1/PHASE2 |
| NCT06991101 |
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma |
RECRUITING | PHASE2 |
| NCT06814496 |
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT06806228 |
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) |
SUSPENDED | PHASE1 |
| NCT06585527 |
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma |
RECRUITING | PHASE1 |
| NCT06562621 |
Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma |
COMPLETED | PHASE1/PHASE2 |
| NCT06533163 |
Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial |
RECRUITING | NA |
| NCT06496971 |
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients |
RECRUITING | PHASE3 |
| NCT06466031 |
Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] |
RECRUITING | NA |
